Families and clinicians shaping ethical standards for personalized care in rare neurological diseases
Official title: Stakeholders of Rare Diseases Informing Values In Neuroethics
Run by St. Jude Children's Research Hospital · NCT07314736 · Data updated 2026-11-12
This project will talk with patients, families, clinicians, and researchers to see which ethical issues matter most when using personalized treatments for children with ultrarare neurological disorders.
Quick facts
| Study type | Observational |
|---|---|
| Sex | All |
| Enrollment | 385 (estimated) |
| Sponsor | St. Jude Children's Research Hospital Academic / other |
| Locations | 1 site (Memphis, Tennessee) |
| Status | Recruiting |
| Started | July 8, 2026 |
| Main results expected | January 2031 |
| Study ends | January 2031 |
| Registry record updated | July 13, 2026 |
| Trial ID | NCT07314736 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are primary caregivers and patients (patients ≤ 25 years; children under 21 at enrollment) with a genetic or suspected genetic ultrarare pediatric-onset neurological disorder, plus involved family members and relevant clinicians or researchers.
✕Probably not a fit
People without a pediatric-onset rare neurological condition, those not part of an affected family network, or patients with expected survival under one year are unlikely to gain direct benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This mixed-methods effort uses validated surveys, semi-structured interviews, and focus groups to capture the perspectives of patients, primary caregivers, other family members, and non-family stakeholders about personalized n-of-few approaches in pediatric rare neurological diseases. Enrolled caregiver–patient dyads will complete quality-of-life and related inventories at baseline and periodically over time while interviews and focus groups elicit experiences and recommendations for consent, communication, and trial conduct. Quantitative measures will include trust in providers and researchers, resilience, and perceived utility of patient-reported outcome measures, and qualitative analysis will identify themes to inform best practices. The overall goal is to produce a practical framework to guide ethical design and communication for personalized interventions in catastrophic pediatric RND.
Why it matters
Potential benefit: If successful, the project could produce a best-practice framework that improves informed consent, communication, and respect for family values in personalized pediatric RND interventions.
How similar studies have gone: Previous qualitative and survey-based ethics research in rare disease and pediatric contexts has informed guidelines, but applying these methods specifically to n-of-few personalized interventions in catastrophic pediatric RND is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Group 1 (Parental Caregiver and Patient Participants) * Parental/primary caregiver with a child who has a genetic diagnosis of an ultrarare disorder with pediatric onset, or a clinical diagnosis with a suspected genetic etiology. * Child is under 21 years of age at the time of enrollment. * Child has an expected survival of at least one year following study enrollment. * Patients (age ≤ 25 years) with a genetic diagnosis of an ultrarare disorder with pediatric onset, or clinical diagnosis with suspected genetic etiology. * Willingness to provide verbal informed consent (or assent, as appropriate) to participate Group 2 (Other Family) * Family member of a Group 1 participant who plays an active role in the child's life or care. * Includes siblings (≥ 13 years of age), grandparents, or other non-primary caregivers directly affected by the child's diagnosis. * Demonstrated familiarity with the child's medical and family experience. * Willingness to provide verbal informed consent (or assent, as appropriate) to participate. Group 3 (Non-Family Stakeholders) * Individuals currently engaged, or recently active, in clinical care, research, advocacy or policy work related to pediatric-onset rare genetic disorders. * May include clinicians (e.g., neurologists, genetic counselors, nurses, child-life specialists, home-health staff), members of patient-advocacy organizations, institutional-review-board (IRB) members, payers, sponsors, funders, or representatives of hospital systems or regulatory agencies. * Willingness to provide verbal informed consent to participate in semi-structured interviews or focus groups Exclusion Criteria: * Limited English proficiency * Unable to complete the survey materials or complete the interviews in English. * Inability or unwillingness of research participant to give verbal informed consent (in English) * Condition or chronic illness, which in the opinion of the PI/Co-I, makes participation unsafe or untenable (i.e., cognitive impairment, concurrent acute morbidity).
Where it's running
-
St. Jude Children's Research Hospital
Memphis, Tennessee, United States Recruiting
Study contacts
- Principal investigator: Liza M. Johnson, MD, MPH, MSB — St. Jude Children's Research Hospital
- Study coordinator: Liza M. Johnson, MD, MPH, MSB
- Email: referralinfo@stjude.org
- Phone: 888-226-4343
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ask Questions About Clinical Trials: A Tool to Help Patients Discuss Trials
This study tests a patient-friendly brochure called the ASQ-CT to see if it helps adults with cancer, heart disease, or neurologic conditions talk with their providers about clinical trials.
-
Postoperative breathing problems after (adeno)tonsillectomy in children with sleep apnea
See how common breathing problems are after (adeno)tonsillectomy in children with obstructive sleep apnea and which factors raise the risk.
-
Registry and natural history of epilepsy-dyskinesia syndromes
This registry will collect health data and biological samples from people of all ages who have a genetic diagnosis of epilepsy-dyskinesia syndromes to see how their genes relate to their movement and seizure symptoms over time.
-
Investigating the health effects of harmful algal blooms
This study is trying to see how exposure to toxins from harmful algal blooms affects people's health, especially their brain and immune system, by monitoring participants over time.
-
Using a serious game to help children with neurological disorders improve upper limb function
This study is testing a fun game designed to help children aged 4 to 17 with neurological disorders improve their hand movements and overall arm function during rehabilitation.
-
Combined whole-brain MRI to predict recovery after cardiac arrest
This study tests whether personalized whole-brain MRI connectivity maps can better predict six-month neurological recovery in adults who remain unconscious after cardiac arrest compared with standard predictors.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.